MGEN - Signal Genetics Stock Price, News & Analysis

$8.04 0.30 (3.88 %)
(As of 11/24/2017 11:07 AM ET)
Previous Close$7.74
Today's Range$7.70 - $8.11
52-Week Range$4.65 - $18.00
Volume108,800 shs
Average Volume66,893 shs
Market Capitalization$179.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93

About Signal Genetics (NASDAQ:MGEN)

Signal Genetics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.


Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A

Debt

Debt-to-Equity Ratio0.04%
Current Ratio7.11%
Quick Ratio7.11%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.34 million
Price / Sales53.70
Cash FlowN/A
Price / CashN/A
Book Value$1.75 per share
Price / Book4.59

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($8.93)
Net Income$-12,670,000.00
Net Margins-720.38%
Return on Equity-80.31%
Return on Assets-64.59%

Miscellaneous

Employees45
Outstanding Shares22,310,000

Frequently Asked Questions for Signal Genetics (NASDAQ:MGEN)

What is Signal Genetics' stock symbol?

Signal Genetics trades on the NASDAQ under the ticker symbol "MGEN."

How were Signal Genetics' earnings last quarter?

Signal Genetics, Inc. (NASDAQ:MGEN) issued its quarterly earnings data on Wednesday, November, 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.12. The medical research company earned $1.63 million during the quarter, compared to the consensus estimate of $0.72 million. Signal Genetics had a negative return on equity of 80.31% and a negative net margin of 720.38%. View Signal Genetics' Earnings History.

Where is Signal Genetics' stock going? Where will Signal Genetics' stock price be in 2017?

3 brokers have issued 1-year target prices for Signal Genetics' stock. Their forecasts range from $17.00 to $29.00. On average, they expect Signal Genetics' share price to reach $23.00 in the next twelve months. View Analyst Ratings for Signal Genetics.

What are Wall Street analysts saying about Signal Genetics stock?

Here are some recent quotes from research analysts about Signal Genetics stock:

  • 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (11/17/2017)
  • 2. Chardan Capital analysts commented, "We see 6 positives in the MRG-106 oral presentation at EORTC The MRG-106 oral presentation at EORTC shows promising signals on the mycosis fungoides form of CTCL. On Saturday, October 13th, at the European Organisation for Research and Treatment of Cancer (EORTC) Global Task Force meeting, miRagen Therapeutics presented new interim phase I data of microRNA-155 inhibitor, MRG-106, in the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL). The results showed 22/23 (96%) of MRG-106-treated patients had improvements in skin disease, when treated with either subcutaneous (subQ) or intravenous MRG-106, as measured by the maximal change in the modified Severity Weighted Assessment Tool (mSWAT) score, which measures the severity of skin disease over a patient’s body." (10/16/2017)

Who are some of Signal Genetics' key competitors?

Who owns Signal Genetics stock?

Signal Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.13%), BSW Wealth Partners (0.10%), Russell Investments Group Ltd. (0.07%) and Seaward Management Limited Partnership (0.06%). Company insiders that own Signal Genetics stock include Adam Scott Levy and Kyle Lefkoff. View Institutional Ownership Trends for Signal Genetics.

Who bought Signal Genetics stock? Who is buying Signal Genetics stock?

Signal Genetics' stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BSW Wealth Partners, Russell Investments Group Ltd. and Seaward Management Limited Partnership. View Insider Buying and Selling for Signal Genetics.

How do I buy Signal Genetics stock?

Shares of Signal Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Signal Genetics' stock price today?

One share of Signal Genetics stock can currently be purchased for approximately $8.04.

How big of a company is Signal Genetics?

Signal Genetics has a market capitalization of $179.37 million and generates $3.34 million in revenue each year. The medical research company earns $-12,670,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis. Signal Genetics employs 45 workers across the globe.

How can I contact Signal Genetics?

Signal Genetics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Signal Genetics (MGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Signal Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Signal Genetics (NASDAQ:MGEN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.00 (186.07% upside)

Consensus Price Target History for Signal Genetics (NASDAQ:MGEN)

Price Target History for Signal Genetics (NASDAQ:MGEN)

Analysts' Ratings History for Signal Genetics (NASDAQ:MGEN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Chardan CapitalReiterated RatingBuy$29.00N/AView Rating Details
8/18/2017WedbushReiterated RatingBuyLowView Rating Details
6/1/2017Cowen IncInitiated CoverageOutperformMediumView Rating Details
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
1/8/2016HC WainwrightInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Signal Genetics (NASDAQ:MGEN)

Earnings by Quarter for Signal Genetics (NASDAQ:MGEN)

Earnings History by Quarter for Signal Genetics (NASDAQ MGEN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.39)($0.27)$0.72 million$1.63 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.47)($0.34)$0.46 million$0.72 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.24)($0.60)$1.00 million$0.46 millionViewN/AView Earnings Details
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)$0.60 million$0.66 millionViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)$0.73 millionViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 million$0.65 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.05)($0.43)$1.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Signal Genetics (NASDAQ:MGEN)
2017 EPS Consensus Estimate: ($1.16)
2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.32)($0.32)($0.32)
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Signal Genetics (NASDAQ:MGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Signal Genetics (NASDAQ MGEN)

Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 22.45%
Insider Trades by Quarter for Signal Genetics (NASDAQ:MGEN)
Institutional Ownership by Quarter for Signal Genetics (NASDAQ:MGEN)

Insider Trades by Quarter for Signal Genetics (NASDAQ MGEN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Adam Scott LevyInsiderBuy200$7.55$1,510.00View SEC Filing  
3/10/2017Kyle LefkoffDirectorSell5,800$14.34$83,172.00View SEC Filing  
3/8/2017Kyle LefkoffDirectorSell15,000$15.40$231,000.00View SEC Filing  
2/28/2017Kyle LefkoffDirectorSell10,258$13.89$142,483.62View SEC Filing  
2/23/2017Kyle LefkoffDirectorSell5,902$14.14$83,454.28View SEC Filing  
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Signal Genetics (NASDAQ MGEN)

Source:
DateHeadline
Cannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head ReviewCannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head Review
www.americanbankingnews.com - November 22 at 3:42 PM
Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)
www.americanbankingnews.com - November 21 at 5:52 PM
BG Medicine (BGMD) and Signal Genetics (MGEN) Critical SurveyBG Medicine (BGMD) and Signal Genetics (MGEN) Critical Survey
www.americanbankingnews.com - November 21 at 1:52 PM
BG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head ReviewBG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head Review
www.americanbankingnews.com - November 20 at 1:30 AM
Signal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment ResearchSignal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:56 PM
Cannabis Science (CBIS) versus Signal Genetics (MGEN) Critical ReviewCannabis Science (CBIS) versus Signal Genetics (MGEN) Critical Review
www.americanbankingnews.com - November 17 at 3:08 AM
Cannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head SurveyCannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head Survey
www.americanbankingnews.com - November 16 at 11:14 PM
Signal Genetics (MGEN) vs. BG Medicine (BGMD) Head-To-Head SurveySignal Genetics (MGEN) vs. BG Medicine (BGMD) Head-To-Head Survey
www.americanbankingnews.com - November 15 at 9:12 PM
ETFs with exposure to Miragen Therapeutics, Inc. : November 14, 2017ETFs with exposure to Miragen Therapeutics, Inc. : November 14, 2017
finance.yahoo.com - November 15 at 6:19 AM
Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 4:39 PM
Signal Genetics, Inc. (MGEN) Releases  Earnings ResultsSignal Genetics, Inc. (MGEN) Releases Earnings Results
www.americanbankingnews.com - November 9 at 6:04 PM
Miragen Therapeutics, Inc. to Host Earnings CallMiragen Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:01 PM
miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 6:01 PM
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual MeetingmiRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting
finance.yahoo.com - November 2 at 6:19 AM
miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017
finance.yahoo.com - November 2 at 6:19 AM
miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics ConferencemiRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference
finance.yahoo.com - October 18 at 7:02 AM
Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106
finance.yahoo.com - October 16 at 8:14 PM
Signal Genetics, Inc. (MGEN) Receives "Buy" Rating from Chardan CapitalSignal Genetics, Inc. (MGEN) Receives "Buy" Rating from Chardan Capital
www.americanbankingnews.com - October 16 at 6:30 AM
miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force MeetingmiRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting
finance.yahoo.com - October 14 at 3:03 AM
miRagen Therapeutics to Present at the Chardan Inaugural Gene Therapy ConferencemiRagen Therapeutics to Present at the Chardan Inaugural Gene Therapy Conference
finance.yahoo.com - October 4 at 7:46 AM
ETFs with exposure to Miragen Therapeutics, Inc. : October 3, 2017ETFs with exposure to Miragen Therapeutics, Inc. : October 3, 2017
finance.yahoo.com - October 4 at 7:46 AM
ETFs with exposure to Miragen Therapeutics, Inc. : September 19, 2017ETFs with exposure to Miragen Therapeutics, Inc. : September 19, 2017
finance.yahoo.com - September 20 at 6:18 AM
Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 9:44 PM
miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary FibrosismiRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis
finance.yahoo.com - September 12 at 1:19 AM
Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International CongressMiragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress
finance.yahoo.com - September 2 at 6:12 AM
BioTelemetry (BEAT) & Signal Genetics (MGEN) Head to Head ReviewBioTelemetry (BEAT) & Signal Genetics (MGEN) Head to Head Review
www.americanbankingnews.com - August 29 at 8:06 PM
Reviewing Signal Genetics (MGEN) and BioTelemetry (BEAT)Reviewing Signal Genetics (MGEN) and BioTelemetry (BEAT)
www.americanbankingnews.com - August 27 at 2:28 AM
Reviewing Signal Genetics (MGEN) & BioTelemetry (BEAT)Reviewing Signal Genetics (MGEN) & BioTelemetry (BEAT)
www.americanbankingnews.com - August 24 at 8:38 AM
Signal Genetics, Inc. (MGEN) Given Consensus Rating of "Buy" by AnalystsSignal Genetics, Inc. (MGEN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 19 at 12:52 PM
Contrasting Signal Genetics (MGEN) & BioTelemetry (BEAT)Contrasting Signal Genetics (MGEN) & BioTelemetry (BEAT)
www.americanbankingnews.com - August 19 at 10:48 AM
Signal Genetics (MGEN) Buy Rating Reaffirmed at WedbushSignal Genetics' (MGEN) Buy Rating Reaffirmed at Wedbush
www.americanbankingnews.com - August 18 at 4:32 PM
Signal Genetics, Inc. (MGEN) Posts Quarterly  Earnings ResultsSignal Genetics, Inc. (MGEN) Posts Quarterly Earnings Results
www.americanbankingnews.com - August 12 at 10:40 AM
Signal Genetics, Inc. (NASDAQ:MGEN) Rating Reiterated by Chardan CapitalSignal Genetics, Inc. (NASDAQ:MGEN) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - August 12 at 6:34 AM
miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 12 at 5:15 AM
Reviewing BioTelemetry (BEAT) and Signal Genetics (NASDAQ:MGEN)Reviewing BioTelemetry (BEAT) and Signal Genetics (NASDAQ:MGEN)
www.americanbankingnews.com - August 11 at 10:52 PM
miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare ConferencemiRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 11:58 PM
Signal Genetics (MGEN) versus BioTelemetry (BEAT) Financial SurveySignal Genetics (MGEN) versus BioTelemetry (BEAT) Financial Survey
www.americanbankingnews.com - August 1 at 2:08 PM
Signal Genetics (NASDAQ:MGEN) & BG Medicine (BGMD) Head-To-Head SurveySignal Genetics (NASDAQ:MGEN) & BG Medicine (BGMD) Head-To-Head Survey
www.americanbankingnews.com - July 27 at 2:42 PM
Comparing BG Medicine (BGMD) & Signal Genetics (MGEN)Comparing BG Medicine (BGMD) & Signal Genetics (MGEN)
www.americanbankingnews.com - July 26 at 12:26 AM
Signal Genetics, Inc. (NASDAQ:MGEN) Given Average Recommendation of "Buy" by AnalystsSignal Genetics, Inc. (NASDAQ:MGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 25 at 3:10 PM
miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing BellmiRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - July 22 at 6:26 AM
Comparing BG Medicine (BGMD) and Signal Genetics (MGEN)Comparing BG Medicine (BGMD) and Signal Genetics (MGEN)
www.americanbankingnews.com - July 21 at 2:26 PM
BG Medicine (BGMD) versus Signal Genetics (MGEN) Head-To-Head ReviewBG Medicine (BGMD) versus Signal Genetics (MGEN) Head-To-Head Review
www.americanbankingnews.com - July 21 at 2:24 PM
Miragen Therapeutics (MGEN) Presents At Jefferies 2017 Global Healthcare Conference - SlideshowMiragen Therapeutics (MGEN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 10:23 AM
Miragen Therapeutics (MGEN) Presents At UBS Global Healthcare Conference 2017 - SlideshowMiragen Therapeutics (MGEN) Presents At UBS Global Healthcare Conference 2017 - Slideshow
seekingalpha.com - May 24 at 10:44 AM
miRagen Therapeutics (MGEN) Presents Interim Results from MRG-201 Phase 1 Clinical TrialmiRagen Therapeutics (MGEN) Presents Interim Results from MRG-201 Phase 1 Clinical Trial
www.streetinsider.com - April 27 at 7:05 PM
4:15 pm Miragen Therapeutics reported recent clinical and financial highlights along with anticipated milestones for 20174:15 pm Miragen Therapeutics reported recent clinical and financial highlights along with anticipated milestones for 2017
us.rd.yahoo.com - April 4 at 3:51 AM
MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and ExhibitsMIRAGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - March 31 at 6:38 PM
MIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrants Certifying Accountant, Change in Directors orMIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change in Directors or
biz.yahoo.com - March 30 at 6:49 PM
MIRAGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportMIRAGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 6:33 PM

Social Media

Financials

Chart

Signal Genetics (NASDAQ MGEN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.